ClinicaliQ Trial Snapshot
- Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma — Active Not Recruiting • Phase II • Oncology • NCT01979523.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective with or without GSK2141795 in treating patients with metastatic uveal melanoma. Conditions: Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 Interventions: Laboratory Biomarker Analysis, Pharmacological Study,…